All In Biotech

BLA 125477 · Eli Lilly and CO

Cyramza

Ramucirumab · Injection · Vascular Endothelial Growth Factor Receptor 2 Antagonist

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Apr 21, 2014

Approved uses

8

Original approval plus efficacy supplements

Registered trials

178

28 Phase 3, 25 recruiting

FAERS reports

6,320

5,943 serious, 1,693 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 9, 2026.

CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) 1.1 Gastric Cancer CYRAMZA ® , as a single agent or in combination with paclitaxel, is indicated for the treatment of adults with advanced or metastatic, gastric or gastro-esophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. 1.2 Non-Small Cell Lung Cancer CYRAMZA, in combination with erlotinib, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal...

Mechanism: Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGFR2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 7, 2025 Supplement 49 · Efficacy · priority review OrphanLabelLetter
  • Jan 27, 2025 Supplement 48 · Efficacy OrphanLabelLetter
  • May 29, 2020 Supplement 34 · Efficacy LetterLabel
  • May 10, 2019 Supplement 29 · Efficacy OrphanLetter
  • Apr 24, 2015 Supplement 11 · Efficacy LetterLabel
  • Dec 12, 2014 Supplement 7 · Efficacy · priority review LabelLetter
  • Nov 5, 2014 Supplement 2 · Efficacy OrphanLabelLetter
  • Apr 21, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLabelSummary Review
2 products under this application
  • CYRAMZA · RAMUCIRUMAB 500MG/50ML · INJECTABLE, INJECTION · Prescription
  • CYRAMZA · RAMUCIRUMAB 100MG/10ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ramucirumab" as an intervention, any sponsor and status, largest first.

All 178 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression817
  • death614
  • interstitial lung disease301
  • neutropenia268
  • febrile neutropenia265
  • decreased appetite234
  • diarrhoea229
  • off label use218
  • nausea209
  • disease progression204
  • fatigue203
  • hypertension194

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20115
201217
201313
2014131
2015405
2016471
2017621
2018687
2019630
2020519
2021628
2022533
2023502
2024474
2025386
2026298

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cyramza (Ramucirumab)

2024 spending

$5.0M

Beneficiaries

106

448 claims

Per beneficiary

$47,536

$143.76 per unit

View as table
YearSpending
2020$2,738,813
2021$3,028,499
2022$3,653,499
2023$3,797,757
2024$5,038,823

Part B: Cyramza (Ramucirumab) · HCPCS J9308

2024 spending

$138M

Beneficiaries

3,080

14,487 claims

Per beneficiary

$44,726

2024 ASP limit $70.56 per unit

View as table
YearSpending
2020$130,155,956
2021$116,423,797
2022$122,952,659
2023$133,899,400
2024$137,755,156

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 282 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.